Sign in
Taking peopleNo phase

Registry following adults with sudden blood clots in the lungs

Follows adults with acute pulmonary embolism to learn about their care and outcomes.

Key facts

Who runs it
Medical University of Warsaw
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Pulmonary Embolism WArsaw REgistry
Status
Recruiting
People taking part
1,500 people, planned
Started
1 Jan 2008
Expected to end
31 Dec 2028
Type of study
Observational, 2 groups
Record updated
27 October 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed sudden blood clot in the lungs (acute pulmonary embolism). It is an observational registry that collects data on their care and outcomes.

Age
18 Years and older
Sex
All
Disease stage
Acute pulmonary embolism, confirmed by objective tests.

Main reasons for not taking part

  • People who do not give consent cannot join.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • objectively confirmed pulmonary embolism
  • Informed consent for the participation in the study, according to the requirements of the ethics committee

Who cannot take part

  • lack of consent

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Initiated in January 2008, The PE-aWARE (Pulmonary Embolism WArsaw REgistry) is an on-going single-centre prospective observational study of patients with confirmed acute pulmonary embolism (APE). Extensive data on consecutive patients with pulmonary embolism is collected and stored. The main objective is to collect and provide information on patients' characteristics, management, and outcome with the purpose of decreasing mortality in APE, the occurrence of bleeding, and the frequency of thromboembolic recurrences. Moreover, the PE-aWARE registry serves as a basis for creating predictive scores for clinicians which aid patient management. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death.

The 2 groups in the trial

  • Complicated outcome

    The patients meet at least one of the following criteria: 1. systolic blood pressure \< 90 mmHg for at least 15 minutes 2. need for catecholamine administration because of persistant arterial hypotension or shock 3. need for mechanical ventilation 4. need for cardiopulmonary resuscitation 5. bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding).

  • Non-complicated outcome

    The patients meet none of the following criteria: 1. systolic blood pressure \< 90 mmHg for at least 15 minutes 2. need for catecholamine administration because of persistant arterial hypotension or shock 3. need for mechanical ventilation 4. need for cardiopulmonary resuscitation 5. bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pulmonary Embolism WArsaw REgistry
Plain-language title
Registry following adults with sudden blood clots in the lungsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
27 October 2023